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Abstract
Purpose During rejection, leukocytes are recruited from
the peripheral circulation into the graft leading to the
damage of endothelial cells, capillary perfusion failure and
graft loss. Chemokines play a pivotal role in the recruit-
ment of leukocytes to the endothelium. Viral macrophage
inﬂammatory protein-II (vMIP-II), a human herpes virus-8
DNA-encoded protein, is a broad-spectrum chemokine
antagonist. The aim of the study was to prove the beneﬁcial
activity of vMIP-II treatment on acute rat kidney allograft
damage.
Methods Heterotopic rat kidney transplantation was per-
formed in the Fischer 344 to Lewis transplantation model
and animals were treated with vMIP-II (2 9 15 lgo r
100 lg/day) for 7 days. Rejection-induced damage was
analyzed by histology, and microcirculatory changes
within the graft were analyzed by in vivo microscopy.
Results Viral macrophage inﬂammatory protein-II sig-
niﬁcantly improved acute glomerular damage and tubulo-
interstitial inﬂammation and lowered the extent of vascular
and tubulointerstitial damage of the treated allografts.
Functional microcirculation of peritubular capillaries was
signiﬁcantly improved in vivo, and the ﬁrm adherence of
leukocytes was signiﬁcantly reduced by vMIP-II treatment.
Conclusions The administration of the broad-spectrum
antagonist vMIP-II improved acute renal allograft damage,
mainly by a reduction in leukocyte recruitment with a sub-
sequently improved renal cortical microcirculation in vivo.
Keywords Chemokine  Virokine  vMIP-II 
Inﬂammation  Allograft rejection
Introduction
The inﬁltration of leukocytes is a key feature in acute
allograft rejection [1]. Endothelial cells play an important
role in the rejection process because they promote both the
recruitment and extravasation of recipient leukocytes [2].
On the endothelial surface glycosaminoglycans bind an
immobilized gradient of chemokines, which upregulate
integrin activity and thereby mediate the arrest of rolling
leukocytes with the attraction of subgroups of leukocytes
[3].
Chemokines are structurally related, low molecular
weight (8–12 kDa) proteins, which belong to a superfamily
of molecules. They are divided into four groups based on
the spacing of the ﬁrst two conserved cysteines at the
amino termini of the chemotactic proteins: XC, CC, CXC
and CX3C [3]. Chemokines have the ability to bind to
multiple receptors and exert pleiotropic functions due to
their redundant binding ability. This makes the chemokine
J. Bedke and T. Stojanovic contributed equally to this work.
Present Address:
J. Bedke (&)
Department of Urology, Eberhard Karls University Tuebingen,
Hoppe-Seyler-Str. 3, 72076 Tu ¨bingen, Germany
e-mail: bedke@live.com
T. Stojanovic
Department of Thoracic, Heart and Vascular Surgery,
University of Go ¨ttingen, Go ¨ttingen, Germany
J. Bedke  E. Kiss  C.-L. Behnes  H.-J. Gro ¨ne
Department of Cellular and Molecular Pathology,
German Cancer Research Center, Heidelberg, Germany
A. E. Proudfoot
Merck Serono Pharmaceutical Research Institute,
Geneva, Switzerland
123
World J Urol (2010) 28:537–542
DOI 10.1007/s00345-010-0556-0network very robust, because blocking one speciﬁc che-
mokine receptor can be potentially overruled by the acti-
vation of other chemokine receptors. In acute and chronic
renal allograft rejection, many chemokines and chemokine
receptors can be detected in the graft, but relatively few
appear to be of importance as demonstrated by animal
studies. In acute renal allograft rejection, the selective
blockade of the CC chemokine receptors CCR1, CCR5 and
CXCR3 led to reduced allograft damage [1, 4, 5].
Broad-spectrum chemokine antagonists may curtail the
redundancy within the chemokine network. The Kaposi’s
sarcoma-associated human herpes virus-8 encodes for the
viral macrophage inhibitory protein II (vMIP-II). In vitro,
this virokine has antagonistic activity on the chemokine
receptors CCR1, CCR2, CCR5, CXCR3 and CXCR4, and
is an agonist to CCR3 and CCR8. Furthermore, vMIP-II
inhibits the chemotactic activity of the rat chemokines
CCL2 (MCP-1), CCL4 (MIP-1b), CCL5 (RANTES) on
activated leukocytes [6]. In vivo vMIP-II prolongs allograft
survival in a model of cardiac and corneal transplantation
[7, 8].
The leukocyte–endothelial cell interaction has delete-
rious effects on perfusion of grafts peritubular capillaries.
The deterioration of capillary perfusion can be measured
prior to histological signs of acute rejection [9]. Thus,
the graft’s microcirculation is a sensitive parameter of
rejection-induced damage [10]. Owing to the broad-
spectrum antagonistic activity, vMIP-II is an interesting
candidate to ameliorate acute renal allograft rejection.
The aim of this study was to test vMIP-II activity in
acute rejection of renal allografts and to examine
microvascular perfusion in peritubular capillaries in
acute-rejecting rat kidneys by means of in vivo
microscopy.
Materials and methods
Animals and renal transplantation experiment
Inbred male rats purchased from Charles River Labora-
tories GmbH (Sulzfeld, Germany) were used for all
experiments. F344 RT1
lvl rats (230–250 g) served as
donors for kidney transplants. Lewis rats (LEW RT1
l,
200–230 g) served as recipients. All experiments were in
accordance with the German legislation on the protection
of animals. Renal transplantation was performed by a
modiﬁed technique from Lee [11] as previously described
[4]. The right kidney of the recipient was left in place to
enhance allograft rejection [4] and to serve as a control
for the effects of vMIP-II. Warm ischemia time of the
donor kidney was 40 min, cold ischemia time approxi-
mately 20 min.
Experimental protocol and experimental groups
Viral macrophage inﬂammatory protein-II was kindly
provided by Serono Pharmaceutical Research Institute
(Geneva, Switzerland) and dissolved in 0.3 ml sterile water
at the respective dosage. The animals were treated with two
different doses intravenously injected over the penile vein:
A dose of 100 lg once per day (HD-vMIP-II) or a dose of
15 lg twice a day (LD-vMIP-II) was given. The initial
dose of 100 lg/day was chosen as previous experiments
with the chemokine receptor antagonist Met-RANTES had
proven to be beneﬁcial in a rat kidney transplantation
model [1] and then decreased to 30 lg as the broad-spec-
trum antagonistic activity of vMIP-II might show inhibi-
tory activity already at lower dosages.
The experimental groups were as follows:
Group 1, histology:
Group 1a: treated with sterile water for 7 days
(n = 11).
Group 1b: treated with vMIP-II at 2 9 15 g/day for
7 days (n = 5).
Group 1c: treated with vMIP-II at 1 9 100 lg/day for
7 days (n = 4).
Group 2, in vivo microscopy:
Group 2a: treated with sterile water for 7 days
(n = 8).
Group 2b: treated with vMIP-II at 1 9 100 lg/day
(n = 6).
Histological analysis
Renal allografts were removed in deep anesthesia, quickly
blotted free of blood and processed as required for histol-
ogy: The kidneys were cut into 2-mm slices and immersion
ﬁxed in 4% formaldehyde in phosphate buffered (pH 7.35)
saline (PBS, 99 mM NaH2PO4, 108 mM, NaH2PO4 and
248 mM NaCl) for 24 h at 4C and then embedded in
parafﬁn.
Renal morphologic studies
Light microscopy was performed on 3-lm sections stained
by periodic acid Schiff. In brief, the vascular injury of pre-
glomerular vessels was assessed as showing no injury (0),
sticking of mononuclear cells to the endothelium (0.5),
subendothelial location of mononuclear cells (1), inﬂam-
mation of the media, including transmural inﬁltration
(without necrosis) (2) and ﬁbrinoid necrosis of the vessel
wall and thrombosis of the vessel in addition to the
inﬂammatory reaction (3). The vascular injury was
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123evaluated in whole kidney sections, including the cortex
and outer stripe of outer medulla. An index speciﬁc vas-
cular injury was deﬁned as the percentage of vessels with
the respective degree of injury encountered in a whole
kidney section. The total vascular injury score was calcu-
lated as the sum of all speciﬁc vascular injuries, whereby
the index of vessels with degree 0.5 was multiplied by 0.5,
that of degree 1 by a factor of 1, that of degree 2 by a factor
of 2 and that of degree 3 by a factor of 3.
The glomerular, tubulointerstitial damage and tubulo-
interstitial inﬂammation scores were calculated in the same
way as described for the vascular injury score [10].
Intravital microscopy
Intravital microscopy was performed as previously
described and the technique was adopted for kidney anal-
ysis [9]. In brief, the abdomen was opened and the
encapsulated kidney was placed on a specially constructed
stage to avoid respiratory artefacts. Compression of the
kidney did not occur. During microscopy, the kidney was
continuously rinsed with warm (37C) Ringer solution.
After a stabilization period of 15 min, intraarterial injec-
tion of 0.6 ml 0.5% ﬂuorescein isothiocyanate-labeled
dextran (500,000 D) and 0.2 ml 0.1% rhodamine-6G (both
Sigma-Aldrich, Deisenhofen, Germany) were used to
visualize renal cortical microcirculation and circulating
leukocytes, respectively. Anaphylactic reactions (hypoten-
sion and limb edema) of the dyes were not observed.
By epi-illumination, a magniﬁcation of 9200 and 9400
was achieved with 920 and 940 water immersion objec-
tives. At least ten sites of interest per animal were ran-
domly selected and recorded by means of a CCD video
camera (Kappa opto-electronics GmbH, Gleichen,
Germany).
Analysis of microcirculatory parameters in the renal
cortex of the kidney was performed ofﬂine with an image
analysis system (CapImage; Zeintl, Heidelberg, Germany).
Functional capillary density was deﬁned as the total length
(cm) of perfused capillaries per square centimeter. Red
blood cell velocity was quantiﬁed with the line to shift
diagram method in mm/s [12, 13].
Leukocyte endothelial interaction was analyzed as
adherent leukocytes (stickers) in the peritubular capillary
vessels and were deﬁned as cells that did not move or
detach from the vessel wall within an observation period of
30 s. Leukocytes were counted as cells per observation
area and expressed as cells per area (cells/mm
2).
Statistical analysis
All data are presented as mean ± standard error of mean
(SEM). Data were analyzed by the two-sided non-
parametric Mann–Whitney U test; in case of multiple
comparisons by Kruskal–Wallis test using GraphPad Prism
(GraphPad, La Jolla, CA). A p\0.05 was considered to
show a signiﬁcant difference between two groups.
Results
Effects of vMIP-II on acute rejection and cell
inﬁltration in allografts
In the untreated renal allografts, signs of tubulointerstitial
rejection (interstitial inﬁltration and tubulitis), as well as a
glomerular mononuclear cell inﬁltrate (transplant glomer-
ulitis) and a vascular damage due to the subendothelial
inﬁltration of mononuclear cells (endothelialitis, transmu-
ral arteritis) were observed by day 7. Two concentrations of
vMIP-II (2 9 15 and 100 lg) were studied in the model.
Both dosages of vMIP-II reduced glomerular injury
(control vs. LD-vMIP-II vs. HD-vMIP-II; 33.0 ± 8.0 vs.
14.1 ± 2.1 vs. 8.8 ± 3.0), tubulointerstitial inﬂammation
(115.0 ± 21.5 vs. 67.0 ± 16.2 vs. 35.0 ± 4.1) and tubular
damage (11.0 ± 3.8 vs. 8.5 ± 2.7 vs. 4.4 ± 3.0) (Fig. 1a).
Vascular cell inﬁltration was slightly improved (control vs.
LD-vMIP-II vs. HD-vMIP-II; 45.23 ± 7.5 vs. 35.9 ± 2.9
vs. 33.1 ± 6.0) (Fig. 1a–c). The high dose (100 lg) had
the most prominent effect with a signiﬁcant reduction in
tubulointerstitial inﬂammation (control vs. HD-vMIP-II,
p\0.05) and glomerular injury (control vs. HD-vMIP-II,
p\0.05) (Fig. 1a). The comparison between the high- and
the low-dose treatment group did not show a signiﬁcant
difference between the groups, although a possible dose-
dependant effect was observed for the glomerular damage,
tubulointerstitial inﬂammation and tubulointerstitial damage.
Light microscopy showed no obvious effect of vMIP-II on
the endogenous contralateral kidney (data not shown).
Effect of vMIP-II on graft microcirculation in vivo
Because tubulointerstitial inﬂammation was signiﬁcantly
reduced by day 7 in the HD-vMIP-II group, we performed
an in vivo microscopy to determine microcirculatory
changes of the allograft in vivo.
The untreated allografts showed a sludge of red blood
and mononuclear cells within the capillaries which led to a
capillary obstruction. The distribution of obstructed capil-
laries was discontinuous over the whole observation ﬁeld
with regularly perfused capillaries in between. The analysis
of the functional capillary density, which was deﬁned as
the length of regularly perfused capillaries, was signiﬁ-
cantly higher in vMIP-II treated animals (control vs. HD-
vMIP-II, 99.2 ± 31.4 vs. 186.3 ± 19.5, p\0.05). Within
the perfused capillaries, the red blood cell velocity did not
World J Urol (2010) 28:537–542 539
123signiﬁcantly differ between the groups (control vs. HD-
vMIP-II, 0.457 ± 0.06 vs. 0.534 ± 0.06) (Fig. 2).
Effect of vMIP-II on leukocyte adherence in vivo
Adherent leukocytes were prominent within the peritubular
capillaries as seen by in vivo microscopy. Leukocytes
tended to form clusters obstructing the capillaries. vMIP-II
treatment signiﬁcantly reduced leukocyte adherence in the
grafts (control vs. HD-vMIP-II, 93.1 ± 13.4 vs. 61.2 ±
7.4, p\0.05) (Fig. 2).
Mean arterial blood pressure measurements during in
vivo microscopy did not reveal signiﬁcant differences
between the groups during the observation period (data not
shown).
Discussion
The activation and transmigration of leukocytes from the
peripheral capillaries into the interstitium of the graft is an
important step in renal allograft rejection. The ﬁrst step in
leukocyte recruitment is the rolling of leukocytes along the
endothelial surface through transient interactions between
selectin molecules and their carbohydrate ligands. Then
ﬁrm adherence to activated integrins is mediated by che-
mokines [2, 10]. In this study, the broad-spectrum antag-
onist vMIP-II ameliorated acute rejection induced renal
allograft damage; it signiﬁcantly improved signs of acute
glomerular damage and tubulointerstitial inﬂammation.
The signiﬁcant reduction in mononuclear cells within
the tubulointerstitium of vMIP-II-treated allografts
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Fig. 1 a Inﬂuence of vMIP-II
treatment on acute rejection-
induced histologic changes:
7 days after transplantation, a
reduction in acute rejection with
lower glomerular damage,
vascular rejection,
tubulointerstitial inﬂammation
and tubulointerstitial damage
was observed in both dosages.
The damage was signiﬁcantly
improved for the high dose
treatment group as compared to
control for glomerular damage
and tubulointerstitial
inﬂammation. Vascular
rejection and tubulointerstitial
damage were improved as
compared to untreated controls,
although not signiﬁcantly. A
dose-dependant effect on the
reduction of acute rejection-
induced changes was noted for
the glomerular damage, the
tubulointerstitial inﬂammation
and the tubulointerstitial
damage (n.s. not signiﬁcant,
p\0.05). b Untreated
allografts show a high rate of
adherent and transmigrated
leukocytes at the vessel wall as
a sign of acute vascular
rejection in a preglomerular
artery. c In contrast, vMIP-II
treatment reduced signs of
vascular rejection
(endothelialitis), magniﬁcation
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123prompted us to investigate microcirculatory changes and
leukocyte–endothelial interaction in the peritubular capil-
laries of the allograft in vivo. In vivo microscopy is a
sensitive method to detect microcirculatory changes in
transplantation research even before histological signs of
rejection become clearly visible [9, 14]. In this study, we
have demonstrated that vMIP-II administration improved
functional capillary density, a sensitive marker of graft
damage and reduced ﬁrm leukocyte adherence to the
endothelium of peritubular capillaries in renal cortex.
By the method of in vivo microscopy, glomeruli could
not be demonstrated due to the limited focus depth of the
epi-illumination technique of approximately 50 lm. So far,
direct analysis of ﬂow changes within the afferent and
efferent arterioles and of glomeruli can only be accom-
plished in congenital or experimentally induced hydrone-
phrotic rats with superﬁcial glomeruli [15].
A reduction in leukocytes ﬁrmly adhering to the vessel
wall in vMIP-II-treated animals was also observed in an
in vitro experiment, by which vMIP-II inhibited the
RANTES-triggered arrest of monocytes and Th1-like
lymphocytes to an endothelial layer [16]. Here, vMIP-II
prevented CCR1 and CCR5 receptor internalization, which
mediate arrest and transmigration of these cells [16].
Ischemia/reperfusion (I/R) injury at the time of trans-
plantation is known to negatively inﬂuence later graft
outcome. I/R injury is a risk factor for acute rejection. In a
cerebral infarct model, the intracerebroventricular injection
of vMIP-II in a mice model reduced infarct volume in a
dose-dependant manner [17]. Although the doses of 0.01–
1 lg used in that model were much lower as the ones in our
renal transplantation experiment, I/R injury might have
been beneﬁcially inﬂuenced by vMIP-II treatment at the
time of reperfusion of the allograft. The reduced I/R injury
can subsequently reduce the degree of developing acute
allograft rejection.
A Th1-immune response is believed to be important
during acute renal transplant rejection [18]. Studies of
chemokine expression during acute rejection showed an
increased abundance of mRNAs encoding chemokines
such as interferon-inducible protein-10 (IP-10), RANTES,
MIP-1a, MIP-1b and lymphotactin, as well as the chemo-
kine receptors CCR2 and CCR5, in the absence of upreg-
ulation of CCR3 and CCR8, which are Th2 chemokine
receptor phenotypes [19]. vMIP-II inhibited the ﬁrm arrest
and transmigration of Th1 cells under in vitro ﬂow con-
ditions and exerted an agonistic action on CCR3 driving a
Th2 immune response [16]. Other groups reported that
gene transfer of plasmid DNA encoding vMIP-II into
murine cardiac allografts resulted in a prolonged survival
time of allografts and a marked decrease in donor-speciﬁc
cytotoxic T lymphocytes (CTL) inﬁltrating the grafts with
an inhibition of alloantibody production [8]. vMIP-II
administration has been reported to reduce leukocyte
inﬁltration and glomerulitis in an experimental model of
glomerulonephritis by reducing the chemotactic activity
of MCP-1, MIP-1b, RANTES and fractalkine-induced
chemotaxis of activated leukocytes [6].
The redundancy of the chemokine network was effec-
tively broken by the viral chemokine antagonist vMIP-II in
this study. The result was a lower acute rejection-induced
damage, which was to some extent still present. This shows
that vMIP-II, as a peptide chemokine receptor antagonist,
without a degradation inhibiting protection, is not potent
enough to fully prevent acute rejection-induced damage
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Fig. 2 Microcirculatory changes of vMIP-II treatment. vMIP-II
treatment signiﬁcantly improved functional capillary density
(p\0.05), while red blood cell velocity (RBCV) remained
unchanged. Leukocyte–endothelial interaction was signiﬁcantly
reduced by vMIP-II showing fewer ﬁrm adherent leukocytes at the
vessel wall in vivo (p\0.05)
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123and perfusion disturbance. Nevertheless, a trend to a dose-
dependant effect was observed. The extent of glomerular
damage, tubulointerstitial inﬂammation and tubulointersti-
tial damage was additionally lowered by a high dose
treatment.
A side effect of vMIP-II which dampens the anti-
inﬂammatory response is the concomitant agonistic activity
on Th2-associated receptors, such as CCR3 provoking a
Th2-type response [16]. Data about the antagonistic
activity on CCR5 are contradictory, as vMIP-II as a che-
moattractant attracted CCR5-positive monocytic THP 1
cell in vitro [20]. On the other hand, vMIP-II signiﬁcantly
reduced CCL5-induced rolling of Th1 cells in the ear
vasculature of mice [21]. Here, speciﬁc chemokine recep-
tor inhibitors might allow a more speciﬁc analysis to
reduce acute renal allograft injury. The peptide Met-
RANTES inhibits CCR1 and CCR5 and is better protected
to protein degradation by the added amino acid methionine.
The small molecule antagonist BX471 inhibits speciﬁcally
CCR1 and repertaxin inhibits speciﬁcally CXCR1/2. For
example, the selective blockade of CCR1 not only ame-
liorated acute renal allograft damage, but also beneﬁcially
inﬂuenced chronic allograft nephropathy [1, 4, 22].
In conclusion, the administration of the broad chemo-
kine analog vMIP-II improved the microvascular perfusion
and the histological parameters associated with acute
rejection. Blocking chemokine receptors and/or function
during acute allograft rejection reduced the adherence of
leukocytes to the endothelium of peritubular capillaries.
These results encourage further investigation of chemokine
receptor blockade by broad-spectrum antagonists during
acute allograft rejection. This may further offer the possi-
bility of a dose reduction in immunosuppressants and
hence lower immunosuppressive-induced adverse effects.
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